Literature DB >> 29078922

Myeloproliferative Disorders.

Brian Meier1, John H Burton2.   

Abstract

The emergency providers generally encounters myeloproliferative disorders (MPNs) in 1 of 2 ways: as striking laboratory abnormalities of seeming unknown consequence, or in previously diagnosed patients presenting with complications. The course of patients with MPNs is highly variable, but major complications can arise. Emergent conditions related to hyperviscosity need to be recognized early and treated aggressively. Rapid hydration, transfusion, cytoreduction, and early hematology consultation can be lifesaving. Likewise, although management is not altered, a high index of suspicion for thrombotic complications is required in patients with known MPNs as these are a significant cause of morbidity and mortality.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic myelogenous leukemia; Essential thrombocythemia; Myeloproliferative disorders; Polycythemia vera; Primary myelofibrosis

Mesh:

Year:  2017        PMID: 29078922     DOI: 10.1016/j.hoc.2017.08.007

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  2 in total

Review 1.  Acute hyperviscosity: syndromes and management.

Authors:  Morie A Gertz
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

2.  [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].

Authors:  M Bao; D Y Shi; H X Shi; X L Liu; M H Duan; J L Zhuang; X Du; L Qin; W H Hui; R Liang; M F Wang; Y Chen; D Y Li; W Yang; G S Tang; W H Zhang; X Kuang; W Su; Y Q Han; L M Chen; J H Xu; Z G Liu; J Huang; C T Zhao; H Y Tong; J D Hu; C Y Chen; X Q Chen; Z J Xiao; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-12-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.